Regenxbio
RGNX
About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Employees: 353
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
21% more call options, than puts
Call options by funds: $1.17M | Put options by funds: $972K
20% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 50
16% more capital invested
Capital invested by funds: $298M [Q1] → $345M (+$47.2M) [Q2]
0.24% more ownership
Funds ownership: 83.18% [Q1] → 83.42% (+0.24%) [Q2]
3% less funds holding
Funds holding: 164 [Q1] → 159 (-5) [Q2]
11% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 28
67% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 1 (-2) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
HC Wainwright & Co.
Yi Chen
|
$34
|
Buy
Reiterated
|
8 Sep 2025 |
|
Chardan Capital
Daniil Gataulin
|
$52
|
Buy
Maintained
|
8 Sep 2025 |
|
RBC Capital
Luca Issi
|
$17
|
Outperform
Maintained
|
8 Aug 2025 |
|
Barclays
Gena Wang
|
$37
|
Overweight
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 7 articles about RGNX published over the past 30 days
